Abstract
Abstract 2650
Tumor associated macrophages (TAM) have at least two potential roles in promoting tumor growth: suppression of immune responses and potentiation of angiogenesis. In numerous cancer types, including lymphomas, high M2 type TAM content has been associated with worse prognosis. Rarely, high TAM content correlates with better survival. We have recently shown that CD68 positive TAMs in DLBCL contribute to unfavorable survival after high dose chemotherapy. Here we have extended our analyses on M2 type macrophages and questioned how combination of rituximab with chemotherapy influences TAM-associated clinical outcome.
Expression of CD163 and CCL18, which are primarily expressed in M2 type macrophages, were identified immunohistochemically from samples of 101 de novo DLBCL patients treated with rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen (immunochemotherapy). With a median follow-up of 65 months, (range 16–114 months), 5-year progression free survival (PFS) was 70% and overall survival (OS) 73%. 29 DLBCL patients previously treated with up front high dose chemotherapy served as a control group.
Correlation between CD163 and CCL18 positive TAMs was found (rs=0.427, p<0.001). In the Kaplan-Meier analyses the cutoff level of 67% was found to best discriminate between subgroups with different outcomes. Consistent with previous data, chemotherapy-treated patients with high CD163 or CCL18 positive TAM counts displayed a significantly inferior OS and PFS than the low group (Table). In contrast, after rituximab containing regimen, the patients with high CD163 and CCL18 positive TAM content tended to have favorable survival. Among the patients with low counts in both CD163 and CCL18 positive TAMs, PFS and OS were found to be significantly worse in comparison to others.
| Survival . | Marker . | Immunochemotherapy group . | Control group . | ||||
|---|---|---|---|---|---|---|---|
| Low (%) . | High (%) . | P-value . | Low (%) . | High (%) . | P-value . | ||
| 5-year OS | CD163 | 70 | 80 | 0.235 | 75 | 33 | 0.019 |
| CCL18 | 69 | 84 | 0.151 | 74 | 33 | 0.037 | |
| CD163+CCL18 | 65 | 85 | 0.035 | 100 | 38 | 0.003 | |
| 5-year PFS | CD163 | 66 | 82 | 0.091 | 75 | 40 | 0.054 |
| CCL18 | 68 | 80 | 0.206 | 74 | 39 | 0.131 | |
| CD163+CCL18 | 63 | 83 | 0.040 | 75 | 42 | 0.013 | |
| Survival . | Marker . | Immunochemotherapy group . | Control group . | ||||
|---|---|---|---|---|---|---|---|
| Low (%) . | High (%) . | P-value . | Low (%) . | High (%) . | P-value . | ||
| 5-year OS | CD163 | 70 | 80 | 0.235 | 75 | 33 | 0.019 |
| CCL18 | 69 | 84 | 0.151 | 74 | 33 | 0.037 | |
| CD163+CCL18 | 65 | 85 | 0.035 | 100 | 38 | 0.003 | |
| 5-year PFS | CD163 | 66 | 82 | 0.091 | 75 | 40 | 0.054 |
| CCL18 | 68 | 80 | 0.206 | 74 | 39 | 0.131 | |
| CD163+CCL18 | 63 | 83 | 0.040 | 75 | 42 | 0.013 | |
In contrast to data on chemotherapy treated DLBCL or other lymphoma types, M2 type TAM content is associated with favorable prognosis in DLBCL patients after immunochemotherapy.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
